It is well known that physicochemical properties of recombinant proteins can be heavily affected during changes in the production process.
Thus, it is mandatory to carefully investigate the similarities and differences of therapeutic Mabs when the production process has been changed.
Comparability must be demonstrated by an array of physicochemical and biological methods as required by the regulatory authorities.